文献速递术前评估与围术期医学区域麻醉与超声

腹腔镜胆囊切除术后新斯的明与舒更葡糖逆转肌松对术后尿潴留的影响:随机对照试验

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine versus Sugammadex in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Controlled Trial.
PubMed 文献 · Anesth Analg · 2026-03-06

该随机对照试验纳入235例腹腔镜胆囊切除术患者,比较罗库溴铵肌松后使用舒更葡糖或新斯的明逆转对术后尿潴留(POUR)发生率的影响。结果显示舒更葡糖组POUR发生率显著低于新斯的明组,差异为12.8%(95%CI 4%~22%,P<.001),两组均无重大不良事件。

要点

  • 腹腔镜胆囊切除术后,舒更葡糖逆转罗库溴铵肌松较新斯的明显著降低POUR发生率。
  • POUR定义包括无法排尿且膀胱容量≥300mL、排尿后残余≥200mL或需导尿。
  • 两组均未发生重大不良事件。

核心结论

  • 在腹腔镜胆囊切除术患者中,罗库溴铵肌松后使用舒更葡糖逆转较新斯的明显著降低术后尿潴留发生率,且无重大不良事件。

研究设计与样本

  • 随机对照试验,共纳入235例腹腔镜胆囊切除术患者。

主要发现

  • 舒更葡糖组POUR发生率显著低于新斯的明组,差异为12.8%(95%CI 4%~22%,P<.001)。
  • 两组均无重大不良事件。

关键数值与推荐

  • POUR定义为:无法排尿且膀胱容量≥300mL,或排尿后残余≥200mL,或需导尿。
  • 罗库溴铵诱导剂量0.6mg/kg(理想体重),维持剂量0.15mg/kg(理想体重)。
  • 逆转用药:舒更葡糖2mg/kg(总体重)或新斯的明50~70µg/kg(理想体重)联合格隆溴铵8~10µg/kg(理想体重)。

临床怎么用

  • 对于腹腔镜胆囊切除术患者,选用舒更葡糖逆转罗库溴铵肌松可降低POUR风险,有利于加速康复和同日出院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In an era of fast-track surgery and enhanced recovery protocols, postoperative urinary retention (POUR) remains a common barrier to same-day discharge, contributing to prolonged PACU stays, patient discomfort, and unplanned admissions. Although sugammadex has been associated with a reduced incidence of POUR, no prospective, randomized studies have compared neostigmine and sugammadex for neuromuscular blockade reversal in laparoscopic cholecystectomy. The objective of this study was to determine the incidence of postoperative urinary retention after the reversal of rocuronium-induced neuromuscular blockade with neostigmine versus sugammadex in patients undergoing laparoscopic cholecystectomy. METHODS: A total of 235 patients undergoing laparoscopic cholecystectomy were enrolled. Anesthesia was induced with rocuronium 0.6 mg/kg (ideal body weight, IBW) to facilitate intubation, and moderate neuromuscular blockade was maintained intraoperatively with 0.15 mg/kg (IBW) doses. At the end of surgery, patients received either sugammadex 2 mg/kg (total body weight, TBW) or neostigmine 50 to 70 µg/kg (IBW) with glycopyrrolate 8 to 10 µg/kg (IBW) for reversal. Bladder volumes were assessed via ultrasound before and after attempted voiding. Postoperative urinary retention (POUR) was defined as (1) inability to void with bladder volume ≥ 300 mL, (2) post-void residual ≥ 200 mL, or (3) need for catheterization. The incidence of POUR was recorded as the primary end point. RESULTS: The incidence of POUR was significantly lower with sugammadex compared with neostigmine, difference of 12.8% (95% CI of the difference 4% to 22%, P < .001). There were no major adverse events in either group. CONCLUSIONS: In patients undergoing laparoscopic cholecystectomy, neuromuscular blockade with rocuronium followed by reversal with sugammadex provides a significant reduction in postoperative urinary retention when compared to reversal with neostigmine, without any major adverse effects.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Diesch CE, Vo MX, Salinas K, et al. Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine versus Sugammadex in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Controlled Trial. Anesth Analg. 2026. PMID: 41789933. doi:10.1213/ANE.0000000000008000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。